“…Two major strategies have proved successful in developing ligands targeting the Hv1 VSD: one focused on the use of peptide toxins binding the channel extracellular side ( Alabi et al, 2007 ; Tang et al, 2020 ; Zhao et al, 2018 ) and the other focused on small organic molecules targeting the channel intracellular side ( Hong et al, 2014 ; Hong et al, 2013 ; Kalia and Swartz, 2013 ; Pupo and Gonzalez León, 2014 ). Some of these ligands have found applications as pharmacological tools to study the gating and permeation mechanisms of proton-conducting VSDs ( Chamberlin et al, 2014 ; Gianti et al, 2016 ; Hong et al, 2015 ; Qiu et al, 2013 ; Wobig et al, 2020 ) and the role of Hv1-mediated proton currents in cellular physiology ( Asuaje et al, 2017 ; Mészáros et al, 2020 ; Rennhack et al, 2017 ; Zhao et al, 2018 ). Drug-screening approaches on native proton currents or on other ion channels have led to the identification of additional potential ligands ( Kornilov et al, 2014 ; Shin et al, 2015 ; Shin and Song, 2014 ; Song et al, 2012 ).…”